These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38815631)

  • 1. Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.
    Fujita K; Yamada M; Morishita A; Ono M; Himoto T; Kobara H; Masaki T
    Biochem Pharmacol; 2024 May; 226():116321. PubMed ID: 38815631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-128-3p Mediates Lenvatinib Resistance of Hepatocellular Carcinoma Cells by Downregulating c-Met.
    Xu X; Jiang W; Han P; Zhang J; Tong L; Sun X
    J Hepatocell Carcinoma; 2022; 9():113-126. PubMed ID: 35252056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
    He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
    Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma.
    Li X; Su H; Tang W; Shu S; Zhao L; Sun J; Fan H
    Invest New Drugs; 2024 Apr; 42(2):185-195. PubMed ID: 38372948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
    Rodríguez-Hernández MA; Chapresto-Garzón R; Cadenas M; Navarro-Villarán E; Negrete M; Gómez-Bravo MA; Victor VM; Padillo FJ; Muntané J
    Cell Death Dis; 2020 May; 11(5):339. PubMed ID: 32382022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-administration of MDR1 and BCRP or EGFR/PI3K inhibitors overcomes lenvatinib resistance in hepatocellular carcinoma.
    Sun D; Liu J; Wang Y; Dong J
    Front Oncol; 2022; 12():944537. PubMed ID: 36158676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NQO1 Mediates Lenvatinib Resistance by Regulating ROS-induced Apoptosis in Hepatocellular Carcinoma.
    Xue W; Wang T; Tian WJ; Pang SQ; Zhang HF; Jia WD
    Curr Med Sci; 2024 Feb; 44(1):168-179. PubMed ID: 38217831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells.
    Nakahara M; Fujihara S; Iwama H; Takuma K; Oura K; Tadokoro T; Fujita K; Tani J; Morishita A; Kobara H; Himoto T; Masaki T
    Biomed Rep; 2022 Oct; 17(4):78. PubMed ID: 36158319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
    Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
    J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.
    Fernández-Palanca P; Payo-Serafín T; San-Miguel B; Méndez-Blanco C; Tuñón MJ; González-Gallego J; Mauriz JL
    Acta Pharmacol Sin; 2023 May; 44(5):1066-1082. PubMed ID: 36376373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma.
    Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L
    Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The regulation of APGAT4 on the growth and lenvatinib resistance of hepatocellular carcinoma].
    Li Z; Yang NH; Li B; Sun CY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Apr; 31(4):408-414. PubMed ID: 37248980
    [No Abstract]   [Full Text] [Related]  

  • 13. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
    Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
    Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxysophocarpine suppresses FGFR1-overexpressed hepatocellular carcinoma growth and sensitizes the therapeutic effect of lenvatinib.
    Zhao Z; Song J; Zhang D; Wu F; Tu J; Ji J
    Life Sci; 2021 Jan; 264():118642. PubMed ID: 33148422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
    Ohno K; Shibata T; Ito KI
    Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal adhesion kinase confers lenvatinib resistance in hepatocellular carcinoma via the regulation of lysine-deficient kinase 1.
    Hou W; Gad SA; Ding X; Dhanarajan A; Qiu W
    Mol Carcinog; 2024 Jan; 63(1):173-189. PubMed ID: 37787401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.
    Miyazaki K; Morine Y; Xu C; Nakasu C; Wada Y; Teraoku H; Yamada S; Saito Y; Ikemoto T; Shimada M; Goel A
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MT1JP-mediated miR-24-3p/BCL2L2 axis promotes Lenvatinib resistance in hepatocellular carcinoma cells by inhibiting apoptosis.
    Yu T; Yu J; Lu L; Zhang Y; Zhou Y; Zhou Y; Huang F; Sun L; Guo Z; Hou G; Dong Z; Wang B
    Cell Oncol (Dordr); 2021 Aug; 44(4):821-834. PubMed ID: 33974236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study on the Mechanism of Notch Pathway Mediates the Role of Lenvatinib-resistant Hepatocellular Carcinoma Based on Organoids.
    Feng W; Zhang H; Yu Q; Yin H; Ou X; Yuan J; Peng L
    Curr Mol Med; 2024 Jan; ():. PubMed ID: 38213137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased c‑SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma.
    Takahashi M; Araki T; Yashima H; Nagamine A; Nagano D; Yamamoto K
    Oncol Lett; 2023 Dec; 26(6):529. PubMed ID: 38020292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.